The USPTO granted patent protection for a novel cisplatin analogue combined with eugenol, a compound derived from clove oil, demonstrating enhanced anti-cancer activity. The patent (US12594338B2) covers the chemical compound itself, its synthesis process, pharmaceutical compositions containing the compound, and methods of treating cancer using the compound. CPC classifications include C07F 15/0093 (platinum compounds), A61P 35/00 (antineoplastic agents), and A61K 47/54 (drug conjugates). The patent contains 2 claims.

Pharmaceutical companies and research institutions engaged in oncology drug development should review this patent to assess potential licensing opportunities or to ensure freedom-to-operate for related cancer therapeutics research. Academic medical centers and drug developers working on platinum-based chemotherapy improvements may find this intellectual property relevant to their programs. No immediate compliance action is required as patent grants do not impose regulatory obligations on third parties.